Collegium Pharmaceutical, Inc. (COLL)
After hours:
| Previous Close | 37.51 |
| Open | 37.80 |
| Bid | 37.42 x 200 |
| Ask | 37.58 x 100 |
| Day's Range | 37.30 - 38.32 |
| 52 Week Range | 20.83 - 40.95 |
| Volume | |
| Avg. Volume | 422,441 |
| Market Cap | 1.227B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | 29.08 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“the Nucynta Franchise”
- GlobeNewswire
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Informa
- GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, 2024 (the “Re
